Substituted morpholine compounds for the treatment of...

Details Substituted morpholine compounds for the treatment of... Substituted morpholine compounds for the treatment of...

2005-04-29

2010-02-09

Anderson, Rebecca L (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Four or more ring nitrogens in the bicyclo ring system

Reexamination Certificate

active

07659394

ABSTRACT:
This invention relates to compounds of the formulae Iwherein R1-R8, A, X, and Z are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system disorders.

REFERENCES:
patent: 4116665 (1978-09-01), Krumkalns et al.
patent: 4229449 (1980-10-01), Melloni et al.
patent: 4271160 (1981-06-01), Melloni et al.
patent: 4782054 (1988-11-01), Regnier et al.
patent: 4851423 (1989-07-01), Girijavaliabhanet al.
patent: 4855143 (1989-08-01), Lowey
patent: 5068433 (1991-11-01), Melloni et al.
patent: 5272167 (1993-12-01), Girijavallabhan et al.
patent: 5391735 (1995-02-01), Melloni et al.
patent: 5441985 (1995-08-01), Foreman
patent: 5459144 (1995-10-01), Grijavallabhan et al.
patent: 5750532 (1998-05-01), Girijavallabhan et al.
patent: 5945117 (1999-08-01), El-Rashidy et al.
patent: 6335338 (2002-01-01), Bhatnagar et al.
patent: 6376711 (2002-04-01), Henegar et al.
patent: 6423708 (2002-07-01), Gibbs et al.
patent: 6465458 (2002-10-01), Wong et al.
patent: 6528529 (2003-03-01), Brann et al.
patent: 6610690 (2003-08-01), Wong et al.
patent: 6635675 (2003-10-01), Kranzler et al.
patent: 6656935 (2003-12-01), Yamada et al.
patent: 6797709 (2004-09-01), Yamada et al.
patent: 6831175 (2004-12-01), Li et al.
patent: 2002/0161002 (2002-10-01), Epstein et al.
patent: 2003/0040464 (2003-02-01), Wong et al.
patent: 2003/0144285 (2003-07-01), Brann et al.
patent: 2003/0187026 (2003-10-01), Li et al.
patent: 2003/0199511 (2003-10-01), Li et al.
patent: 2003/0203055 (2003-10-01), Rao et al.
patent: 2003/0229085 (2003-12-01), Blume et al.
patent: 2003/0229095 (2003-12-01), Yamada et al.
patent: 2004/0019116 (2004-01-01), Kranzler et al.
patent: 2004/0034019 (2004-02-01), Tomlinson et al.
patent: 2004/0034101 (2004-02-01), Rao et al.
patent: 2004/0058925 (2004-03-01), Wong et al.
patent: 2004/0142930 (2004-07-01), Yamada et al.
patent: 2004/0147614 (2004-07-01), Wong et al.
patent: 2004/0186148 (2004-09-01), Shankar et al.
patent: 2005/0009927 (2005-01-01), Marek et al.
patent: 2005/0059654 (2005-03-01), Arneric et al.
patent: 2005/0245519 (2005-11-01), Barta et al.
patent: 865.656 (1978-05-01), None
patent: 873.596 (1979-07-01), None
patent: 29 01 032.0 (1979-01-01), None
patent: 2056 589.3 (1979-11-01), None
patent: 0 109 751 (1984-05-01), None
patent: 0427605 (1991-05-01), None
patent: 0 286 495 (1993-05-01), None
patent: 0 274 867 (1994-04-01), None
patent: 1140788 (1999-12-01), None
patent: 1308443 (1999-12-01), None
patent: 2 442 839 (1980-06-01), None
patent: 1138405 (1969-01-01), None
patent: 1 295 447 (1969-11-01), None
patent: 1260886 (1972-01-01), None
patent: 1 310 235 (1973-03-01), None
patent: 2 167 407 (1986-05-01), None
patent: 2004-189738 (2004-07-01), None
patent: WO9111172 (1991-08-01), None
patent: WO9402518 (1994-02-01), None
patent: WO9608487 (1996-03-01), None
patent: WO 96/31487 (1996-10-01), None
patent: WO 96/34851 (1996-11-01), None
patent: WO 97/19059 (1997-05-01), None
patent: WO 98/14433 (1998-04-01), None
patent: WO9830560 (1998-07-01), None
patent: WO9855148 (1998-12-01), None
patent: WO 99/50247 (1999-10-01), None
patent: WO 99/50262 (1999-10-01), None
patent: WO 00/09491 (2000-02-01), None
patent: WO 00/39072 (2000-07-01), None
patent: WO0039072 (2000-07-01), None
patent: WO0059477 (2000-10-01), None
patent: WO 01/05763 (2001-01-01), None
patent: WO0101973 (2001-01-01), None
patent: WO 01/44258 (2001-06-01), None
patent: WO 01/53263 (2001-07-01), None
patent: WO 01/83460 (2001-11-01), None
patent: WO 02/36125 (2002-05-01), None
patent: WO 03/037338 (2003-05-01), None
patent: WO 03/051366 (2003-06-01), None
patent: WO 03/059873 (2003-07-01), None
patent: WO 2004/005255 (2004-01-01), None
patent: WO2004058353 (2004-01-01), None
patent: WO 2004/013356 (2004-02-01), None
patent: WO 2004/017977 (2004-03-01), None
patent: WO 2004/018441 (2004-03-01), None
patent: WO 2004/018840 (2004-03-01), None
patent: WO 2004018440 (2004-03-01), None
patent: WO2004/048860 (2004-07-01), None
patent: WO 2004/058353 (2004-07-01), None
patent: WO 2004/058353 (2004-07-01), None
patent: WO 2005/000309 (2005-01-01), None
patent: WO 2005/000309 (2005-01-01), None
patent: WO 2005/020975 (2005-03-01), None
patent: WO 2005/020975 (2005-03-01), None
patent: WO 2005/020976 (2005-03-01), None
patent: WO 2005/020976 (2005-03-01), None
patent: WO 2005/021095 (2005-03-01), None
patent: WO 2005/021095 (2005-03-01), None
patent: WO 2005/023802 (2005-03-01), None
patent: WO 2005/066144 (2005-07-01), None
patent: WO 2005/076412 (2005-08-01), None
patent: WO 2005/105100 (2005-11-01), None
J. G. Topliss, “A Manual Method for Applying the Hansch Approach to Drug Design”, Journal of Medicinal Chemistry, 1977, vol. 20, No. 4, 463-469.
J. A. H. Lainton, et al., “Design and Synthesis of A Diverse Morpholine Template Library”, J. Comb. Chem., 2003, 5, 400-407.
Patani et al. (Chem. Rev., 1996, 96, 3147-3176.
T. Spencer, et al., “Adults with Attention-Deficit/hyperactivity Disorder: A Controversial Diagnosis,” J Clin Psychiatry, 1998, pp. 59-68, Suppl. 7.
J. B. Schweitzer, et al., “Advance in the Pathophysiology and Treatement of Psychiatric Disorders: Implications for Internal Medicine,” Medical Clinics of North America, May 2001, pp. 757-777 vol. 85 No. 3.
D. P. Cantwell, “Attention Deficit Disorder: A Review of the Past 10 Years”, J Am Acad Child Adolesc Psychiatry, Aug. 1996, pp. 978-987, vol. 35, No. 8.
J. Elia, et al., “Treatment of Attention Deficit Hyperactivity”, Eng. J. Med, Mar. 1999, pp. 780-788, vol. 340, No. 10.
E. E. Nolan, et al., “Teacher Reports of DSM-IV ADHD, ODD, and CD Symptoms in Schoolchildren,” J Am Acad Child Adolesc Psychiatry, Feb. 2001, pp. 241249, vol. 40, No. 2.
M. Dulcan, et al., “Practice Parameters for the Assessment and Treatment of Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder,” Oct. 1997, pp. 85-121, vol. 36, Suppl. 10.
Cantwell, D., et al., “Attention Deficit Disorder: A Review of the Past 10 Years”, J Am Acad Child Adolesc Psychiatry, Aug. 1996, pp. 978-987, vol. 35, No. 8.
Cryan, J., et al., “Noradrenergic lesions differentially alter the antidepressant-like effects of reboxetine in a modified forced swim test” Euro J Pharm, 2002, pp. 197-205, vol. 436, No. 3.
Dulcan, M., et al., “Practice Parameters for the Assessment and Treatment of Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder,” Oct. 1997, pp. 85-12, vol. 36, Suppl. 10.
Elia, J., et al., “Treatment of Attention Deficit Hyperactivity”, Eng. J. Med, Mar. 1999, pp. 780-788, vol. 340, No. 10.
Harkin, A., et al., “The Effect of Reboxetine in Some Preclinical Tests Predictive of Antidepressant Activity”, J. Psychopharmacology, 1997, pp. A39, vol. 11, No. 3, Suppl.
Melloni, P.; et al., “Configurational Studies On 2-Alpha-(2-Ethoxyphenoxy) Benzylmorpholine FCE 20124”, Tetrahedron, 1985, pp. 1393-1399, vol. 41, No. 7.
Melloni, P., et al., “Potential Antidepressant Agents. Alpha-Aryloxy-Benzyl Derivatives Of Ethanolamine And Morpholine”, Eur. J. Med. Chem. Chim. Ther., 1984, pp. 235-242, vol. 19, No. 3.
Nolan, E., et al., “Teacher Reports of DSM-IV ADHD, ODD, and CD Symptoms in Schoolchildren,” J Am Acad Child Adolesc Psychiatry, Feb. 2001, pp. 241-249, vol. 40, No. 2.
Schou, M., et al., “Preparation and PET Evaluation Of [18F]FMPBM-D2- A Promising Brain Norepinephrine Transporter (Net) Radioligand”, J. Label Compd. Radiopharm., 2003, pp. S59, vol. 46.
Schweitzer, J., et al., “Advance in the Pathophysiology and Treatment of Psychiatric Disorders: Implications for Internal Medicine,” Medical Clinics of North America, May 2001, pp. 757-777, vol. 85, No. 3.
Spencer, T., et al., “Adults with Attention-Deficit/hyperactivity Disorder: A Controversial Diagnosis,” J Clin Psychiatry, 1998, pp. 59-68, Suppl. 7.
Boursier-Neyret, C., et al., “

Affiliated with

Also associated with

Rating

Substituted morpholine compounds for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted morpholine compounds for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted morpholine compounds for the treatment of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4198232